Drug Trial News

RSS

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Study compares two drug combinations for use as deep sedation during oral surgery

The ideal sedative for oral surgery should make the patient comfortable during the surgery and should wear off quickly enough that the patient can leave the dental chair soon after the procedure. Finding the best plan of anesthetic treatment is essential to the success of dental procedures such as the extraction of wisdom teeth.

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

12 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

11 Oct 2012

Women respond much better than men to treatment of CFL with rituximab

Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the highly respected journal "Haematologica".

11 Oct 2012

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

11 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

GSK, Aeras to advance clinical development of TB vaccine

Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

Eli Lilly and Company today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35. Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks. A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.

9 Oct 2012

New neuroprotective agent for stroke patients potentially found

Scientists have shown that a drug called NA-1 results in fewer brain lesions in patients who have undergone surgery to repair a brain aneurysm, compared to placebo, and appears to be safe to use, according to an Article published Online First in The Lancet Neurology.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Drug Trial News

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Study compares two drug combinations for use as deep sedation during oral surgery

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

Women respond much better than men to treatment of CFL with rituximab

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Mayo researchers discover new therapy for patients with neuromyelitis optica

CRI, MedImmune partner to advance cancer immunotherapy research

GSK, Aeras to advance clinical development of TB vaccine

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

New neuroprotective agent for stroke patients potentially found

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News